Cargando…

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax(®) compared with Turbuhaler(®) in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

OBJECTIVE: The objective of this study was to estimate the economic impact of the introduction of DuoResp(®) Spiromax(®), budesonide/formoterol fixed-dose combination (FDC), focusing on an increase in medication adherence due to an enhancement of the inhalation technique for the treatment of COPD pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darbà, Josep, Ramírez, Gabriela, García-Rivero, Juan L, Mayoralas, Sagrario, Pascual, José Francisco, Vargas, Diego, Bijedic, Adi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312689/ https://www.ncbi.nlm.nih.gov/pubmed/28228660 http://dx.doi.org/10.2147/CEOR.S125301

Ejemplares similares

A budget impact analysis of Spiromax(®) compared with Turbuhaler(®) for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions
por: Darbà, Josep, et al.
Publicado: (2016)

Assessment of inhalation errors, training time and patient preference for DuoResp® Spiromax® and Symbicort® Turbuhaler® in patients with asthma and COPD
por: Giner, Jordi, et al.
Publicado: (2020)

Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study
por: Azouz, Wahida, et al.
Publicado: (2015)

Comparison of correct technique and preference for Spiromax®, Easyhaler® and Turbuhaler®: a single-site, single-visit, crossover study in inhaler-naïve adult volunteers
por: Rönmark, Per, et al.
Publicado: (2018)

Evaluation of inhaler handling-errors, inhaler perception and preference with Spiromax, Easyhaler and Turbuhaler devices among healthy Finnish volunteers: a single site, single visit crossover study (Finhaler)
por: Sandler, Niklas, et al.
Publicado: (2016)

Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study
por: Price, David B., et al.
Publicado: (2018)

A randomized, double-blinded, double-dummy efficacy and safety study of budesonide–formoterol Spiromax® compared to budesonide–formoterol Turbuhaler® in adults and adolescents with persistent asthma
por: Virchow, J. Christian, et al.
Publicado: (2016)

Asthma patients prefer Respimat(®) Soft Mist™ Inhaler to Turbuhaler(®)
por: Hodder, Rick, et al.
Publicado: (2009)

Skills in Handling Turbuhaler, Diskus, and Pressurized Metered-Dose Inhaler in Korean Asthmatic Patients
por: Lee, Sang Min, et al.
Publicado: (2011)

Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions
por: Canonica, Giorgio Walter, et al.
Publicado: (2015)

The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients
por: Darbà, Josep, et al.
Publicado: (2015)

Skills in handling Turbuhaler, Diskus in the west of China
por: Wei, Wei, et al.
Publicado: (2023)

Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis
por: Sicras-Mainar, A., et al.
Publicado: (2018)

Utility and effectiveness of Symbicort® Turbuhaler® (oral inhalation containing budesonide and formoterol) in a patient with severe asthma after permanent tracheostomy
por: Maeda, Kohhei, et al.
Publicado: (2018)

A telephone-based survey of current trends, habits and beliefs in patients receiving portable oxygen therapy in Madrid, Spain
por: Mayoralas Alises, Sagrario, et al.
Publicado: (2019)

Relationship between patient dependence and direct medical-, social-, indirect-, and informal-care costs in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis
por: Darbà, Josep, et al.
Publicado: (2019)

Epidemiology and management of parathyroid gland disorders in Spain over 15 years: A retrospective multicentre analysis
por: Darbà, Josep, et al.
Publicado: (2020)

Results after 10 years of colorectal cancer screenings in Spain: Hospital incidence and in-hospital mortality (2011–2016)
por: Darbà, Josep, et al.
Publicado: (2020)

Analysis of the management and costs of headache disorders in Spain during the period 2011–2016: a retrospective multicentre observational study
por: Darbà, Josep, et al.
Publicado: (2020)

Characteristics, management and medical costs of patients with depressive disorders admitted in primary and specialised care centres in Spain between 2011 and 2016
por: Darbà, Josep, et al.
Publicado: (2020)

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

The cost of lost productivity due to premature lung cancer-related mortality: results from Spain over a 10-year period
por: Darbà, Josep, et al.
Publicado: (2019)

Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain
por: Rejas-Gutierrez, Javier, et al.
Publicado: (2021)

Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler
por: Lähelmä, Satu, et al.
Publicado: (2015)

Evaluating Drug Deposition Patterns from Turbuhaler® in Healthy and Diseased Lung Models of Preschool Children
por: Kannan, Ravishekar, et al.
Publicado: (2022)

Medication economic burden of antidepressant non-adherence in Spain
por: Gutiérrez-Abejón, Eduardo, et al.
Publicado: (2023)

Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
por: Voorham, Jaco, et al.
Publicado: (2018)

Real-world evidence effect of budesonide+formoterol Spiromax on patients with asthma and chronic obstructive pulmonary disease in Sweden
por: Janson, Christer, et al.
Publicado: (2019)

Three-month validation of a turbuhaler electronic monitoring device: implications for asthma clinical trial use
por: Pilcher, Janine, et al.
Publicado: (2015)

Economic Impact of Low Adherence to COPD Management Guidelines in Spain
por: Miravitlles, Marc, et al.
Publicado: (2021)

Economic Evaluation of the Use of FeNO for the Diagnosis and Management of Asthma Patients in Primary Care in Sweden
por: Darbà, Josep, et al.
Publicado: (2021)

Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain
por: Darbà, Josep, et al.
Publicado: (2013)

Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
Publicado: (2019)

Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
Publicado: (2018)

A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler(®) to Budesonide/Formoterol Easyhaler(®)
por: Syk, Jörgen, et al.
Publicado: (2019)

Palliative care in COPD patients: A challenge in modern medicine
por: Lobato, Salvador Díaz, et al.
Publicado: (2015)

Clinical and Economic Consequences of Inhaled Corticosteroid Doses and Particle Size in Triple Inhalation Therapy for COPD: Real-Life Study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2020)

Correction to: A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler(®) to Budesonide/Formoterol Easyhaler(®)
por: Syk, Jörgen, et al.
Publicado: (2019)

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain
por: Romero-Gomez, Manuel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7pup6pf9e4mgems2d3c39toond